Asprosin and miRNA Expression in Young Women With Metabolic Syndrome (ASPRO-MetS)
Association Between Serum Asprosin Concentration and Expression of Selected miRNAs With Risk Factors and Components of Metabolic Syndrome in Young Women: Diagnostic Perspectives
Metabolic syndrome is a major risk factor for cardiovascular disease and type 2 diabetes, and its prevalence in young adults is increasing. Early identification of individuals at risk may improve prevention strategies. This observational, cross-sectional case-control study investigates the relationship between serum asprosin concentration, the expression of six selected circulating microRNAs, and the components and risk factors of metabolic syndrome in young women aged 18 to 35 years. Two equally sized groups will be compared: women meeting NCEP ATP III criteria for metabolic syndrome and healthy age-matched controls. Participants attend a single study visit during which fasting blood samples, anthropometric and body composition measurements, blood pressure, and validated questionnaires assessing physical activity, diet, sleep quality, perceived stress, and quality of life are collected. The study aims to determine whether asprosin and the selected microRNA profile have diagnostic value as biomarkers of metabolic syndrome in this population.
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Description détaillée
Background. Metabolic syndrome is a complex disorder characterized by the coexistence of abdominal obesity, hypertension, dyslipidemia, and impaired glucose metabolism, resulting in an increased risk of cardiovascular disease and type 2 diabetes mellitus. Although established diagnostic criteria exist, there is an ongoing need for novel biomarkers that may improve early detection and clarify the pathophysiological mechanisms involved, particularly in young adults, in whom the condition remains under-investigated.
Asprosin is a fasting-induced adipokine implicated in glucose metabolism, insulin resistance, and obesity. Circulating microRNAs are considered promising molecular biomarkers involved in metabolic regulation and inflammatory pathways. Brain-derived neurotrophic factor (BDNF) and cortisol are additional candidate mediators linking metabolic, psychological, and sleep-related factors.
Objectives. The primary objective is to determine whether serum asprosin concentration and the expression of six selected circulating microRNAs (miR-15a-5p, miR-197-3p, miR-23a-3p, miR-21-5p, miR-146a-5p, miR-223-3p) differ between young women with metabolic syndrome and healthy age-matched women. Secondary objectives are to compare the prevalence of individual metabolic syndrome components, body composition, anthropometric, insulin resistance and atherogenic indices, physical activity, diet, sleep quality, perceived stress, and health-related quality of life between the groups, and to assess correlations between asprosin, the microRNA profile, and these variables.
Design and participants. A total of 110 women aged 18 to 35 years will be enrolled into two equally sized groups: women with metabolic syndrome without other comorbidities requiring continuous pharmacotherapy (MetS, n=55) and healthy women (CON, n=55). Sample size was calculated using G*Power 3.1.9.7; assuming a two-tailed independent-samples comparison, alpha = 0.05, effect size d = 0.5, and power = 0.80, the minimum required sample is 51 participants per group. Recruitment is continuous and conducted among young women in the Podhale region and the Malopolska Province, primarily in the academic community.
Procedures. Eligibility is screened via an online form. Eligible participants attend a single study visit of approximately 90 minutes at the Institute of Medicine of the University of Applied Sciences in Nowy Targ. After written informed consent, the following are performed: fasting venous blood collection (18 mL, antecubital vein, vacuum system, by qualified medical personnel); blood pressure measurement; anthropometric measurements (body height, body mass, waist, abdominal and hip circumference) and body composition assessment by bioelectrical impedance analysis (BIA); and completion of validated questionnaires - International Physical Activity Questionnaire (IPAQ) and 7-day Physical Activity Recall (7day-PAR), Pittsburgh Sleep Quality Index (PSQI), Perceived Stress Scale (PSS-10), Food Frequency Questionnaire (FFQ) or KomPAN together with the Fitatu dietary application, and the Short Form-36 Health Survey (SF-36).
Laboratory analyses performed immediately in a certified external laboratory: complete blood count, fasting glucose, glycated hemoglobin, insulin, and lipid profile. Plasma is separated by centrifugation at 2500 RCF for 15 minutes, aliquoted, and stored at -80 degrees C until batch analysis of asprosin, BDNF, cortisol, and the microRNA panel.
Metabolic syndrome diagnosis. Made by a physician according to NCEP ATP III criteria for women, requiring at least three of five components: triglycerides greater than 150 mg/dL; HDL cholesterol below 50 mg/dL; blood pressure greater than 130/85 mmHg or antihypertensive treatment; fasting glucose greater than 100 mg/dL or previously diagnosed diabetes; waist circumference greater than 88 cm.
Derived indices. BMI, WHR, WHtR, A Body Shape Index (ABSI), Hip Index (HI), Body Adiposity Index (BAI), Visceral Adiposity Index (VAI), Lipid Accumulation Product (LAP), HOMA-IR, QUICKI, METS-IR, triglyceride-glucose index (TyG), Castelli Risk Index I and II (CRI-I, CRI-II), and Atherogenic Index of Plasma (AIP).
Statistical analysis. Distribution of variables will be assessed using the Shapiro-Wilk test. Between-group comparisons will use the independent-samples t-test or the Mann-Whitney U test as appropriate. Correlations will be assessed using Pearson or Spearman coefficients. Statistical significance will be set at p less than 0.05.
All participants will receive their individual results. Data will be anonymized before analysis and scientific use.
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Contacts et emplacements
Coordonnées de l'étude
Coordonnées de l'étude
- Nom: Małgorzata Kantorowicz, Ph.D.
- Numéro de téléphone: +48 662 251 012
- E-mail: sknmedicus@ans-nt.edu.pl
Sauvegarde des contacts de l'étude
- Nom: Maciej Filipowski, M.D.
- Numéro de téléphone: +48 (18) 26-10-726
- E-mail: ip@ans-nt.edu.pl
Lieux d'étude
-
-
Lesser Poland Voivodeship
-
Nowy Targ, Lesser Poland Voivodeship, Pologne, 34-400
- Recrutement
- Institute of Medicine, University of Applied Sciences in Nowy Targ, Kokoszków 71, 34-400 Nowy Targ, Poland
-
Contact:
- Małgorzata Kantorowicz, Ph.D.
- Numéro de téléphone: +48 662 251 012
- E-mail: malgorzata.kantorowicz@ans-nt.edu.pl
-
Contact:
- Kamil Opar, Master's degree
- Numéro de téléphone: +48 603442732
- E-mail: kamil.opar@ans-nt.edu.pl
-
Sous-enquêteur:
- Magdalena Więcek, Professor / Full Professor
-
Chercheur principal:
- Małgorzata Kantorowicz, Ph. D.
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Women aged 18 to 35 years recruited from the general and academic population of the Podhale region and the Malopolska Province, Poland, through university websites, e-mail, social media, local press, printed posters and leaflets, and information meetings. Eligibility is screened using an online questionnaire. Enrolled participants form two equally sized groups: women diagnosed with metabolic syndrome according to NCEP ATP III criteria and healthy women of comparable age.
La description
Inclusion Criteria:
- Female sex
- Age 18 to 35 years
- Regular menstrual cycle
- Not engaged in competitive sports training in any discipline
- Non-smoker
- No alcohol abuse
- No continuous pharmacotherapy, with the exception of treatment for diabetes and/or antihypertensive treatment; no use of hormonal contraception
- Written informed consent for study participation and processing of personal data
Exclusion Criteria:
- Age outside the range of 18 to 35 years
- Irregular menstrual cycle
- Pregnancy or breastfeeding
- Continuous pharmacotherapy for indications other than diabetes and/or hypertension, including any form of hormonal contraception (oral, transdermal, vaginal, implant, injectable or intrauterine)
- Competitive sports training in any discipline
- Current smoking
- Alcohol abuse
- Lack of written informed consent for study participation and processing of personal data
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: CASE_CONTROL
- Perspectives temporelles: CROSS_SECTIONAL
Nombre de groupes / cohortes
Cohortes et interventions
Groupe / CohorteGroupe / Cohorte |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Metabolic Syndrome Group (MetS)
Women aged 18-35 years meeting NCEP ATP III criteria for metabolic syndrome (at least three of five components: triglycerides greater than 150 mg/dL; HDL cholesterol below 50 mg/dL; blood pressure greater than 130/85 mmHg or antihypertensive treatment; fasting glucose greater than 100 mg/dL or previously diagnosed diabetes; waist circumference greater than 88 cm), with no other comorbidity requiring continuous pharmacotherapy. Target n=55. |
Fasting venous blood collection for measurement of serum asprosin, BDNF and cortisol concentrations, and expression of six circulating microRNAs (miR-15a-5p, miR-197-3p, miR-23a-3p, miR-21-5p, miR-146a-5p, miR-223-3p), in addition to complete blood count, glucose, glycated hemoglobin, insulin, and lipid profile. Blood pressure measurement, anthropometric measurements and bioelectrical impedance body composition analysis, and completion of validated questionnaires (IPAQ, 7day-PAR, PSQI, PSS-10, FFQ/KomPAN with the Fitatu application, SF-36). |
|
Control Group (CON)
Healthy women aged 18-35 years not meeting NCEP ATP III criteria for metabolic syndrome, matched for age, not receiving continuous pharmacotherapy. Target n=55. |
Fasting venous blood collection for measurement of serum asprosin, BDNF and cortisol concentrations, and expression of six circulating microRNAs (miR-15a-5p, miR-197-3p, miR-23a-3p, miR-21-5p, miR-146a-5p, miR-223-3p), in addition to complete blood count, glucose, glycated hemoglobin, insulin, and lipid profile. Blood pressure measurement, anthropometric measurements and bioelectrical impedance body composition analysis, and completion of validated questionnaires (IPAQ, 7day-PAR, PSQI, PSS-10, FFQ/KomPAN with the Fitatu application, SF-36). |
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Serum asprosin concentration
Délai: At the single study visit (Day 1)
|
Fasting serum asprosin concentration measured by enzyme-linked immunosorbent assay, compared between women with metabolic syndrome and healthy controls. Reported in ng/mL. |
At the single study visit (Day 1)
|
|
Expression of selected circulating microRNAs
Délai: At the single study visit (Day 1)
|
Relative expression of six circulating microRNAs (miR-15a-5p, miR-197-3p, miR-23a-3p, miR-21-5p, miR-146a-5p, miR-223-3p) quantified in plasma by reverse-transcription quantitative PCR. Expression is normalized using ath-miR159a as an exogenous spike-in control and hsa-miR-186-5p as a reference. All six analytes are measured by the same method and reported in the same unit of measure, relative fold change, with results reported separately for each microRNA. |
At the single study visit (Day 1)
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Prevalence of individual metabolic syndrome components
Délai: At the single study visit (Day 1)
|
Proportion of participants in each group meeting each of the five NCEP ATP III components: elevated triglycerides, reduced HDL cholesterol, elevated blood pressure, elevated fasting glucose, and abdominal obesity. Reported as percentage of participants. |
At the single study visit (Day 1)
|
|
Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)
Délai: At the single study visit (Day 1)
|
HOMA-IR calculated from fasting glucose and fasting insulin as (fasting insulin in microU/mL x fasting glucose in mg/dL) / 405, compared between the metabolic syndrome group and the control group. Reported as an index score (unitless). Higher values indicate greater insulin resistance. |
At the single study visit (Day 1)
|
|
Castelli Risk Index I
Délai: At the single study visit (Day 1)
|
Ratio of total cholesterol to HDL cholesterol, calculated from the fasting lipid profile and compared between the metabolic syndrome group and the control group. Reported as a ratio (unitless). Higher values indicate greater atherogenic risk. |
At the single study visit (Day 1)
|
|
Body fat percentage
Délai: At the single study visit (Day 1)
|
Body fat percentage (PBF) measured by bioelectrical impedance analysis, compared between the metabolic syndrome group and the control group. Reported as a percentage of total body mass. |
At the single study visit (Day 1)
|
|
Serum brain-derived neurotrophic factor (BDNF) concentration
Délai: At the single study visit (Day 1)
|
Fasting serum BDNF concentration measured by enzyme-linked immunosorbent assay, compared between groups and correlated with metabolic syndrome components. Reported in ng/mL. |
At the single study visit (Day 1)
|
|
Serum cortisol concentration
Délai: At the single study visit (Day 1)
|
Fasting serum cortisol concentration measured by immunoassay, compared between groups and correlated with perceived stress and sleep quality scores. Reported in micrograms/dL. |
At the single study visit (Day 1)
|
|
Quantitative Insulin Sensitivity Check Index (QUICKI)
Délai: At the single study visit (Day 1)
|
QUICKI calculated from fasting glucose and fasting insulin as 1 / (log fasting insulin in microU/mL + log fasting glucose in mg/dL), compared between the metabolic syndrome group and the control group. Reported as an index score (unitless). Higher values indicate greater insulin sensitivity. |
At the single study visit (Day 1)
|
|
Metabolic Score for Insulin Resistance (METS-IR)
Délai: At the single study visit (Day 1)
|
METS-IR calculated from fasting glucose, fasting triglycerides, body mass index and HDL cholesterol, compared between the metabolic syndrome group and the control group. Reported as an index score (unitless). Higher values indicate greater insulin resistance. |
At the single study visit (Day 1)
|
|
Triglyceride-Glucose Index (TyG)
Délai: At the single study visit (Day 1)
|
TyG index calculated as the natural logarithm of (fasting triglycerides in mg/dL x fasting glucose in mg/dL) / 2, compared between the metabolic syndrome group and the control group. Reported as an index score (unitless). Higher values indicate greater insulin resistance. |
At the single study visit (Day 1)
|
|
Castelli Risk Index II
Délai: At the single study visit (Day 1)
|
Ratio of LDL cholesterol to HDL cholesterol, calculated from the fasting lipid profile and compared between the metabolic syndrome group and the control group. Reported as a ratio (unitless). Higher values indicate greater atherogenic risk. |
At the single study visit (Day 1)
|
|
Atherogenic Index of Plasma (AIP)
Délai: At the single study visit (Day 1)
|
Base-10 logarithm of the ratio of fasting triglycerides to HDL cholesterol, both expressed in mmol/L, compared between the metabolic syndrome group and the control group. Reported as a log-transformed ratio (unitless). Higher values indicate greater atherogenic risk. |
At the single study visit (Day 1)
|
|
Fat-free mass
Délai: At the single study visit (Day 1)
|
Fat-free mass (FFM) measured by bioelectrical impedance analysis, compared between the metabolic syndrome group and the control group. Reported in kilograms. |
At the single study visit (Day 1)
|
|
Body Mass Index (BMI)
Délai: At the single study visit (Day 1)
|
Body mass index calculated as body mass in kilograms divided by the square of body height in metres, compared between the metabolic syndrome group and the control group. Reported in kg/m^2. |
At the single study visit (Day 1)
|
|
Waist-to-Hip Ratio (WHR)
Délai: At the single study visit (Day 1)
|
Ratio of waist circumference to hip circumference, both measured in centimetres with an anthropometric tape, compared between the metabolic syndrome group and the control group. Reported as a ratio (unitless). |
At the single study visit (Day 1)
|
|
Waist-to-Height Ratio (WHtR)
Délai: At the single study visit (Day 1)
|
Ratio of waist circumference to body height, both measured in centimetres, compared between the metabolic syndrome group and the control group. Reported as a ratio (unitless). |
At the single study visit (Day 1)
|
|
A Body Shape Index (ABSI)
Délai: At the single study visit (Day 1)
|
ABSI calculated from waist circumference, body mass index and body height according to Krakauer and Krakauer, compared between the metabolic syndrome group and the control group. Reported as an index score. Higher values indicate greater central adiposity relative to body size. |
At the single study visit (Day 1)
|
|
Hip Index (HI)
Délai: At the single study visit (Day 1)
|
Hip Index calculated from hip circumference adjusted for body height and body mass, compared between the metabolic syndrome group and the control group. Reported as an index score. |
At the single study visit (Day 1)
|
|
Body Adiposity Index (BAI)
Délai: At the single study visit (Day 1)
|
BAI calculated from hip circumference and body height, compared between the metabolic syndrome group and the control group. Reported as estimated body fat expressed as a percentage of total body mass. |
At the single study visit (Day 1)
|
|
Visceral Adiposity Index (VAI)
Délai: At the single study visit (Day 1)
|
VAI calculated from waist circumference, body mass index, fasting triglycerides and HDL cholesterol using the sex-specific formula for women, compared between the metabolic syndrome group and the control group. Reported as an index score (unitless). |
At the single study visit (Day 1)
|
|
Lipid Accumulation Product (LAP)
Délai: At the single study visit (Day 1)
|
LAP calculated for women as (waist circumference in cm minus 58) multiplied by fasting triglycerides in mmol/L, compared between the metabolic syndrome group and the control group. Reported in cm x mmol/L. |
At the single study visit (Day 1)
|
Autres mesures de résultats
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Physical activity level assessed by the International Physical Activity Questionnaire (IPAQ)
Délai: At the single study visit (Day 1)
|
Habitual physical activity assessed using the International Physical Activity Questionnaire, compared between the metabolic syndrome group and the control group. Reported as total physical activity in MET-minutes per week. Higher values indicate a higher level of physical activity. |
At the single study visit (Day 1)
|
|
Sleep quality
Délai: At the single study visit (Day 1)
|
Sleep quality assessed using the Pittsburgh Sleep Quality Index (PSQI). Global score range 0 to 21; higher scores indicate worse sleep quality, with a score above 5 indicating poor sleep quality. |
At the single study visit (Day 1)
|
|
Perceived stress level
Délai: At the single study visit (Day 1)
|
Perceived stress assessed using the 10-item Perceived Stress Scale (PSS-10). Score range 0 to 40; higher scores indicate higher perceived stress. |
At the single study visit (Day 1)
|
|
Daily energy intake
Délai: At the single study visit (Day 1)
|
Habitual daily energy intake assessed using a Food Frequency Questionnaire or the KomPAN questionnaire together with the Fitatu dietary application, compared between the metabolic syndrome group and the control group. Reported in kilocalories per day. |
At the single study visit (Day 1)
|
|
Health-related quality of life
Délai: At the single study visit (Day 1)
|
Health-related quality of life assessed using the Short Form-36 Health Survey (SF-36). Domain and summary scores range 0 to 100; higher scores indicate better perceived health. |
At the single study visit (Day 1)
|
|
Waist circumference
Délai: At the single study visit (Day 1)
|
Waist circumference measured with an anthropometric tape according to standard protocol, compared between the metabolic syndrome group and the control group. Reported in centimetres. |
At the single study visit (Day 1)
|
|
Abdominal circumference
Délai: At the single study visit (Day 1)
|
Abdominal circumference measured with an anthropometric tape at the level of the umbilicus, compared between the metabolic syndrome group and the control group. Reported in centimetres. |
At the single study visit (Day 1)
|
|
Hip circumference
Délai: At the single study visit (Day 1)
|
Hip circumference measured with an anthropometric tape at the level of the greatest gluteal protrusion, compared between the metabolic syndrome group and the control group. Reported in centimetres. |
At the single study visit (Day 1)
|
|
Body mass
Délai: At the single study visit (Day 1)
|
Body mass measured on a calibrated scale integrated with the bioelectrical impedance analyser, compared between groups. Reported in kilograms. |
At the single study visit (Day 1)
|
|
Target body mass
Délai: At the single study visit (Day 1)
|
Target body mass calculated by the bioelectrical impedance analyser from measured body composition, compared between groups. Reported in kilograms. |
At the single study visit (Day 1)
|
|
Fat mass
Délai: At the single study visit (Day 1)
|
Mass of body fat (MBF) measured by bioelectrical impedance analysis, compared between groups. Reported in kilograms. |
At the single study visit (Day 1)
|
|
Soft lean mass
Délai: At the single study visit (Day 1)
|
Soft lean mass (SLM) measured by bioelectrical impedance analysis, compared between groups. Reported in kilograms. |
At the single study visit (Day 1)
|
|
Skeletal muscle mass
Délai: At the single study visit (Day 1)
|
Skeletal muscle mass (SMM) measured by bioelectrical impedance analysis, compared between groups. Reported in kilograms. |
At the single study visit (Day 1)
|
|
Total body water
Délai: At the single study visit (Day 1)
|
Total body water (TBW) measured by bioelectrical impedance analysis, compared between groups. Reported as a percentage of total body mass. |
At the single study visit (Day 1)
|
|
Extracellular water ratio
Délai: At the single study visit (Day 1)
|
Ratio of extracellular water to total body water (ECW ratio) measured by bioelectrical impedance analysis, compared between groups. Reported as a ratio (unitless). |
At the single study visit (Day 1)
|
|
Body cell mass
Délai: At the single study visit (Day 1)
|
Body cell mass (BCM) measured by bioelectrical impedance analysis, compared between groups. Reported in kilograms. |
At the single study visit (Day 1)
|
|
Protein content
Délai: At the single study visit (Day 1)
|
Total body protein content measured by bioelectrical impedance analysis, compared between groups. Reported in kilograms. |
At the single study visit (Day 1)
|
|
Mineral content
Délai: At the single study visit (Day 1)
|
Total body mineral content measured by bioelectrical impedance analysis, compared between groups. Reported in kilograms. |
At the single study visit (Day 1)
|
|
Physical activity energy expenditure assessed by the 7-day Physical Activity Recall (7day-PAR)
Délai: At the single study visit (Day 1)
|
Physical activity energy expenditure over the preceding seven days assessed using the 7-day Physical Activity Recall interview, compared between the metabolic syndrome group and the control group. Reported as mean daily energy expenditure in kilocalories per day. |
At the single study visit (Day 1)
|
|
Macronutrient distribution of the diet
Délai: At the single study visit (Day 1)
|
Contribution of protein, fat and carbohydrate to total daily energy intake, assessed using a Food Frequency Questionnaire or the KomPAN questionnaire together with the Fitatu dietary application, compared between the metabolic syndrome group and the control group. Reported as a percentage of total daily energy intake for each macronutrient. |
At the single study visit (Day 1)
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Collaborateurs
Collaborateurs
Les enquêteurs
Les enquêteurs
- Chercheur principal: Małgorzata Kantorowicz, Ph. D., University of Applied Sciences in Nowy Targ
Publications et liens utiles
Publications générales
- Romere C, Duerrschmid C, Bournat J, Constable P, Jain M, Xia F, Saha PK, Del Solar M, Zhu B, York B, Sarkar P, Rendon DA, Gaber MW, LeMaire SA, Coselli JS, Milewicz DM, Sutton VR, Butte NF, Moore DD, Chopra AR. Asprosin, a Fasting-Induced Glucogenic Protein Hormone. Cell. 2016 Apr 21;165(3):566-79. doi: 10.1016/j.cell.2016.02.063. Epub 2016 Apr 14.
- Yuan M, Li W, Zhu Y, Yu B, Wu J. Asprosin: A Novel Player in Metabolic Diseases. Front Endocrinol (Lausanne). 2020 Feb 19;11:64. doi: 10.3389/fendo.2020.00064. eCollection 2020.
- Saklayen MG. The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep. 2018 Feb 26;20(2):12. doi: 10.1007/s11906-018-0812-z.
- Fahed G, Aoun L, Bou Zerdan M, Allam S, Bou Zerdan M, Bouferraa Y, Assi HI. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. Int J Mol Sci. 2022 Jan 12;23(2):786. doi: 10.3390/ijms23020786.
- Krakauer NY, Krakauer JC. A new body shape index predicts mortality hazard independently of body mass index. PLoS One. 2012;7(7):e39504. doi: 10.1371/journal.pone.0039504. Epub 2012 Jul 18.
- Wiecek M, Szymura J, Sproull J, Szygula Z. Whole-Body Cryotherapy Is an Effective Method of Reducing Abdominal Obesity in Menopausal Women with Metabolic Syndrome. J Clin Med. 2020 Aug 30;9(9):2797. doi: 10.3390/jcm9092797.
- Bello-Chavolla OY, Almeda-Valdes P, Gomez-Velasco D, Viveros-Ruiz T, Cruz-Bautista I, Romo-Romo A, Sanchez-Lazaro D, Meza-Oviedo D, Vargas-Vazquez A, Campos OA, Sevilla-Gonzalez MDR, Martagon AJ, Hernandez LM, Mehta R, Caballeros-Barragan CR, Aguilar-Salinas CA. METS-IR, a novel score to evaluate insulin sensitivity, is predictive of visceral adiposity and incident type 2 diabetes. Eur J Endocrinol. 2018 May;178(5):533-544. doi: 10.1530/EJE-17-0883. Epub 2018 Mar 13.
- Li M, Zhang J. Circulating MicroRNAs: Potential and Emerging Biomarkers for Diagnosis of Cardiovascular and Cerebrovascular Diseases. Biomed Res Int. 2015;2015:730535. doi: 10.1155/2015/730535. Epub 2015 May 28.
- Wiecek M, Szymura J, Kusmierczyk J, Lipowska M, Szygula Z. Whole-Body Cryotherapy Improves Asprosin Secretion and Insulin Sensitivity in Postmenopausal Women-Perspectives in the Management of Type 2 Diabetes. Biomolecules. 2023 Oct 31;13(11):1602. doi: 10.3390/biom13111602.
- Wiecek M, Szymura J, Maciejczyk M, Kantorowicz M, Szygula Z. Acute Anaerobic Exercise Affects the Secretion of Asprosin, Irisin, and Other Cytokines - A Comparison Between Sexes. Front Physiol. 2018 Dec 10;9:1782. doi: 10.3389/fphys.2018.01782. eCollection 2018.
- Kusmierczyk J, Wiecek M, Bawelski M, Szygula Z, Rafa-Zablocka K, Kantorowicz M, Szymura J. Pre-exercise cryotherapy reduces myoglobin and creatine kinase levels after eccentric muscle stress in young women. Front Physiol. 2024 Jun 19;15:1413949. doi: 10.3389/fphys.2024.1413949. eCollection 2024.
- Wiecek M, Mardyla M, Szymura J, Kantorowicz M, Kusmierczyk J, Maciejczyk M, Szygula Z. Maximal Intensity Exercise Induces Adipokine Secretion and Disrupts Prooxidant-Antioxidant Balance in Young Men with Different Body Composition. Int J Mol Sci. 2025 Jan 3;26(1):350. doi: 10.3390/ijms26010350.
- Wiecek M, Kusmierczyk J, Szymura J, Kreiner G, Szygula Z. Whole-Body Cryotherapy Alters Circulating MicroRNA Profile in Postmenopausal Women. J Clin Med. 2023 Aug 12;12(16):5265. doi: 10.3390/jcm12165265.
- Kantorowicz M, Szymura J, Szygula Z, Kusmierczyk J, Maciejczyk M, Wiecek M. Nordic Walking at Maximal Fat Oxidation Intensity Decreases Circulating Asprosin and Visceral Obesity in Women With Metabolic Disorders. Front Physiol. 2021 Sep 3;12:726783. doi: 10.3389/fphys.2021.726783. eCollection 2021.
- Wen D, Qiao P, Wang L. Circulating microRNA-223 as a potential biomarker for obesity. Obes Res Clin Pract. 2015 Jul-Aug;9(4):398-404. doi: 10.1016/j.orcp.2015.01.006. Epub 2015 Apr 2.
- Roos J, Enlund E, Funcke JB, Tews D, Holzmann K, Debatin KM, Wabitsch M, Fischer-Posovszky P. miR-146a-mediated suppression of the inflammatory response in human adipocytes. Sci Rep. 2016 Dec 6;6:38339. doi: 10.1038/srep38339.
- Darabi F, Aghaei M, Movahedian A, Elahifar A, Pourmoghadas A, Sarrafzadegan N. Association of serum microRNA-21 levels with Visfatin, inflammation, and acute coronary syndromes. Heart Vessels. 2017 May;32(5):549-557. doi: 10.1007/s00380-016-0913-z. Epub 2016 Oct 26.
- Deiuliis JA. MicroRNAs as regulators of metabolic disease: pathophysiologic significance and emerging role as biomarkers and therapeutics. Int J Obes (Lond). 2016 Jan;40(1):88-101. doi: 10.1038/ijo.2015.170. Epub 2015 Aug 27.
- Karolina DS, Tavintharan S, Armugam A, Sepramaniam S, Pek SL, Wong MT, Lim SC, Sum CF, Jeyaseelan K. Circulating miRNA profiles in patients with metabolic syndrome. J Clin Endocrinol Metab. 2012 Dec;97(12):E2271-6. doi: 10.1210/jc.2012-1996. Epub 2012 Oct 2.
- Ramzan F, D'Souza RF, Durainayagam BR, Milan AM, Markworth JF, Miranda-Soberanis V, Sequeira IR, Roy NC, Poppitt SD, Mitchell CJ, Cameron-Smith D. Circulatory miRNA biomarkers of metabolic syndrome. Acta Diabetol. 2020 Feb;57(2):203-214. doi: 10.1007/s00592-019-01406-6. Epub 2019 Aug 21.
- Saliminejad K, Khorram Khorshid HR, Soleymani Fard S, Ghaffari SH. An overview of microRNAs: Biology, functions, therapeutics, and analysis methods. J Cell Physiol. 2019 May;234(5):5451-5465. doi: 10.1002/jcp.27486. Epub 2018 Nov 23.
- Parrizas M, Novials A. Circulating microRNAs as biomarkers for metabolic disease. Best Pract Res Clin Endocrinol Metab. 2016 Oct;30(5):591-601. doi: 10.1016/j.beem.2016.08.001. Epub 2016 Aug 4.
- Agbu P, Carthew RW. MicroRNA-mediated regulation of glucose and lipid metabolism. Nat Rev Mol Cell Biol. 2021 Jun;22(6):425-438. doi: 10.1038/s41580-021-00354-w. Epub 2021 Mar 26.
- Wiecek M, Szymura J, Sproull J, Szygula Z. Decreased Blood Asprosin in Hyperglycemic Menopausal Women as a Result of Whole-Body Cryotherapy Regardless of Metabolic Syndrome. J Clin Med. 2019 Sep 10;8(9):1428. doi: 10.3390/jcm8091428.
- Mishra I, Duerrschmid C, Ku Z, He Y, Xie W, Silva ES, Hoffman J, Xin W, Zhang N, Xu Y, An Z, Chopra AR. Asprosin-neutralizing antibodies as a treatment for metabolic syndrome. Elife. 2021 Apr 27;10:e63784. doi: 10.7554/eLife.63784.
- Lee T, Yun S, Jeong JH, Jung TW. Asprosin impairs insulin secretion in response to glucose and viability through TLR4/JNK-mediated inflammation. Mol Cell Endocrinol. 2019 Apr 15;486:96-104. doi: 10.1016/j.mce.2019.03.001. Epub 2019 Mar 7.
- Li E, Shan H, Chen L, Long A, Zhang Y, Liu Y, Jia L, Wei F, Han J, Li T, Liu X, Deng H, Wang Y. OLFR734 Mediates Glucose Metabolism as a Receptor of Asprosin. Cell Metab. 2019 Aug 6;30(2):319-328.e8. doi: 10.1016/j.cmet.2019.05.022. Epub 2019 Jun 20.
- Chong B, Kong G, Shankar K, Chew HSJ, Lin C, Goh R, Chin YH, Tan DJH, Chan KE, Lim WH, Syn N, Chan SP, Wang JW, Khoo CM, Dimitriadis GK, Wijarnpreecha K, Sanyal A, Noureddin M, Siddiqui MS, Foo R, Mehta A, Figtree GA, Hausenloy DJ, Chan MY, Ng CH, Muthiah M, Mamas MA, Chew NWS. The global syndemic of metabolic diseases in the young adult population: A consortium of trends and projections from the Global Burden of Disease 2000-2019. Metabolism. 2023 Apr;141:155402. doi: 10.1016/j.metabol.2023.155402. Epub 2023 Jan 28.
- Vishram JK, Borglykke A, Andreasen AH, Jeppesen J, Ibsen H, Jorgensen T, Palmieri L, Giampaoli S, Donfrancesco C, Kee F, Mancia G, Cesana G, Kuulasmaa K, Salomaa V, Sans S, Ferrieres J, Dallongeville J, Soderberg S, Arveiler D, Wagner A, Tunstall-Pedoe H, Drygas W, Olsen MH; MORGAM Project. Impact of age and gender on the prevalence and prognostic importance of the metabolic syndrome and its components in Europeans. The MORGAM Prospective Cohort Project. PLoS One. 2014 Sep 22;9(9):e107294. doi: 10.1371/journal.pone.0107294. eCollection 2014.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies musculo-squelettiques
- Maladies du système nerveux
- Les troubles mentaux
- Troubles nutritionnels
- Maladies métaboliques
- Suralimentation
- Poids
- Troubles du métabolisme du glucose
- Troubles du sommeil et de l'éveil
- Anomalies musculosquelettiques
- Anomalies congénitales
- Hyperinsulinisme
- En surpoids
- Troubles du sommeil, intrinsèques
- Dyssomnies
- Troubles du métabolisme lipidique
- Obésité
- Déformations des membres, congénitales
- Maladies et anomalies congénitales, héréditaires et néonatales
- Conditions pathologiques, signes et symptômes
- Maladies nutritionnelles et métaboliques
- Signes et symptômes
- Syndrome métabolique
- Troubles de l'initiation et du maintien du sommeil
- Résistance à l'insuline
- Dyslipidémies
- Obésité abdominale
- Arachnodactylie
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- SKN/SP/659046/2026
- SKN/SP/659046/2026 (Autre subvention/numéro de financement: Ministry of Science and Higher Education, Poland)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Individual participant data will not be made publicly available. Data are collected under informed consent that specifies use for scientific purposes following anonymization, and the consent does not cover open data sharing. Anonymized aggregate results will be published in a peer-reviewed scientific journal. Requests for anonymized data may be directed to the principal investigator and will be considered subject to approval by the sponsor institution and the bioethics committee.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .